Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial
暂无分享,去创建一个
Amber C. Donahue | X. Mu | R. Motzer | J. Larkin | T. Powles | T. Choueiri | K. Ching | J. Haanen | G. Gravis | B. Alekseev | M. Uemura | S. Pal | M. Campbell | L. Albiges | P. Robbins | S. Hariharan | A. di Pietro | J. Lee | Jing Wang | Weidong Zhang | K. Penkov | A. Chudnovsky | Xiao Wang
[1] S. Tapscott,et al. DUX4 Suppresses MHC Class I to Promote Cancer Immune Evasion and Resistance to Checkpoint Blockade. , 2019, Developmental cell.
[2] X. Mu,et al. Biomarker analyses from JAVELIN Renal 101: Avelumab + axitinib (A+Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC). , 2019, Journal of Clinical Oncology.
[3] T. Powles,et al. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal‐Cell Carcinoma , 2019, The New England journal of medicine.
[4] R. Motzer,et al. Avelumab plus Axitinib versus Sunitinib for Advanced Renal‐Cell Carcinoma , 2019, The New England journal of medicine.
[5] J. Reeves,et al. Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma , 2018, Nature Medicine.
[6] Jennifer G. Lyons,et al. Characteristics, treatment patterns and safety events from 4 cohorts of advanced or metastatic cancer patients based on health care claims data. , 2018 .
[7] J. Larkin,et al. Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial. , 2018, The Lancet. Oncology.
[8] Bohuslav Melichar,et al. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal‐Cell Carcinoma , 2018, The New England journal of medicine.
[9] Michael C. Heinold,et al. The landscape of genomic alterations across childhood cancers , 2018, Nature.
[10] T. Chan,et al. Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab , 2017, Cell.
[11] J. Lunceford,et al. IFN-&ggr;–related mRNA profile predicts clinical response to PD-1 blockade , 2017, The Journal of clinical investigation.
[12] E. Amir,et al. HYPE or HOPE: the prognostic value of infiltrating immune cells in cancer , 2017, British Journal of Cancer.
[13] J. Schlom,et al. Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial. , 2017, The Lancet. Oncology.
[14] N. Neamati,et al. Role of the CXCL8-CXCR1/2 Axis in Cancer and Inflammatory Diseases , 2017, Theranostics.
[15] J. Sosman,et al. Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma , 2017, Cell.
[16] Stuart J. Andrews,et al. Implementation of next generation sequencing into pediatric hematology-oncology practice: moving beyond actionable alterations , 2016, Genome Medicine.
[17] H. Decker,et al. Immunological properties of oxygen-transport proteins: hemoglobin, hemocyanin and hemerythrin , 2016, Cellular and Molecular Life Sciences.
[18] A. Kennedy,et al. Role of lipids in the metabolism and activation of immune cells. , 2016, The Journal of nutritional biochemistry.
[19] P. Ross-Macdonald,et al. Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma , 2016, Clinical Cancer Research.
[20] Keunchil Park,et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial , 2016, The Lancet.
[21] J. Mesirov,et al. The Molecular Signatures Database Hallmark Gene Set Collection , 2015 .
[22] P. Hegde,et al. Immune biomarkers associated with clinical benefit from atezolizumab (MPDL3280a; anti-PD-L1) in advanced urothelial bladder cancer (UBC) , 2015, Journal of Immunotherapy for Cancer.
[23] Erik Sahai,et al. Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity , 2015, Cell.
[24] A. Ribas. Adaptive Immune Resistance: How Cancer Protects from Immune Attack. , 2015, Cancer discovery.
[25] S. Signoretti,et al. Correlation of PD-L1 Tumor Expression and Treatment Outcomes in Patients with Renal Cell Carcinoma Receiving Sunitinib or Pazopanib: Results from COMPARZ, a Randomized Controlled Trial , 2014, Clinical Cancer Research.
[26] W. Huber,et al. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.
[27] A. McKenna,et al. The genomic landscape of pediatric Ewing sarcoma. , 2014, Cancer discovery.
[28] Benjamin Schubert,et al. OptiType: precision HLA typing from next-generation sequencing data , 2014, Bioinform..
[29] Demin Li,et al. A Core Human Primary Tumor Angiogenesis Signature Identifies the Endothelial Orphan Receptor ELTD1 as a Key Regulator of Angiogenesis , 2013, Cancer cell.
[30] The Cancer Genome Atlas Research Network. COMPREHENSIVE MOLECULAR CHARACTERIZATION OF CLEAR CELL RENAL CELL CARCINOMA , 2013, Nature.
[31] Steven J. M. Jones,et al. Comprehensive molecular characterization of clear cell renal cell carcinoma , 2013, Nature.
[32] Yi-Wen Chen,et al. DUX4 Differentially Regulates Transcriptomes of Human Rhabdomyosarcoma and Mouse C2C12 Cells , 2013, PloS one.
[33] Matthew J. Brauer,et al. Identification and Analysis of In Vivo VEGF Downstream Markers Link VEGF Pathway Activity with Efficacy of Anti-VEGF Therapies , 2013, Clinical Cancer Research.
[34] Elaine R. Mardis,et al. Novel mutations target distinct subgroups of medulloblastoma , 2012, Nature.
[35] Abraham P. Fong,et al. DUX4 activates germline genes, retroelements, and immune mediators: implications for facioscapulohumeral dystrophy. , 2012, Developmental cell.
[36] J. Mesirov,et al. Molecular signatures database (MSigDB) 3.0 , 2011, Bioinform..
[37] J. Scheller,et al. The pro- and anti-inflammatory properties of the cytokine interleukin-6. , 2011, Biochimica et biophysica acta.
[38] Kenneth G. C. Smith,et al. FcγRIIB in autoimmunity and infection: evolutionary and therapeutic implications , 2010, Nature Reviews Immunology.
[39] J. Zimmer,et al. Cytokine Levels Correlate with Immune Cell Infiltration after Anti-VEGF Therapy in Preclinical Mouse Models of Breast Cancer , 2009, PloS one.
[40] S. Horvath,et al. WGCNA: an R package for weighted correlation network analysis , 2008, BMC Bioinformatics.
[41] H. Zou,et al. Regularization and variable selection via the elastic net , 2005 .
[42] R. Gray. Modeling Survival Data: Extending the Cox Model , 2002 .
[43] H Nagura,et al. Proliferative activity of intratumoral CD8(+) T-lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathologic demonstration of antitumor immunity. , 2001, Cancer research.
[44] P. Grambsch,et al. Modeling Survival Data: Extending the Cox Model , 2000 .
[45] R. Gill,et al. Cox's regression model for counting processes: a large sample study : (preprint) , 1982 .
[46] Ash A. Alizadeh,et al. SUPPLEMENTARY NOTE , 1879, Botanical Gazette.
[47] Kenneth G. C. Smith,et al. FcγRIIB in autoimmunity and infection: evolutionary and therapeutic implications , 2010, Nature Reviews Immunology.